Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04351893 · ClinicalTrials.gov registry record
Craniofacial Microsomia: Accelerating Understanding of the Significance and Etiology
A clinical trial of Microtia and Microtia-Anotia, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- 935
- Enrollment target
- 10
- Study locations
NCT04351893: Completed study of Microtia and Microtia-Anotia, sponsored by Seattle Children's Hospital.
NCT04351893 is a study of Microtia and Microtia-Anotia that has completed, run by Seattle Children's Hospital. The registered enrollment target is 935 participants, below the 1,399-participant average among 4 other Microtia trials with a reported enrollment target (33% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04351893, a study of Microtia and Microtia-Anotia, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- 935 participants
- Enrollment target
- 10
- Study locations
Study Summary
The CAUSE study is a multicenter study, with domestic (n=4) and international (n=6) study sites. Children and young adults (ages 0-18) who have microtia and/or craniofacial microsomia and their parents are invited to participate. Children and parents are asked to provide a DNA sample (blood or saliva) and are asked to upload a few photos of their face. Parents are asked a short interview. Participants are able to participate from home or at one of four domestic sites.
Primary Outcome
To identify genetic variants related to the CFM spectrum using whole genome sequencing
Conditions Studied
Study Locations (10)
Other
- Pontificia Universidad Javeriana - Bogotá
- ICESI - Cali
- Pontificia Universidad Javeriana - Cali
- Clínica Comfamiliar Risaralda - Pereira
- Hospital Edgardo Rebagliati Martins - Lima
- Instituto de Genética Médica y Molecular (INGEMM) - Madrid
California
- Children's Hospital Los Angeles - Los Angeles
North Carolina
- University of North Carolina - Chapel Hill
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 935 participants |
| Start Date | 2018-02-23 |
| Est. Completion | 2023-08-30 |
What the finished NCT04351893 record still lists
NCT04351893 is an observational study that tracks outcomes without assigning an intervention. The registered 935 participants enrollment target is mid-sized for trials with a published cap, below the 1,399-participant average among 4 other Microtia trials with a reported enrollment target (33% lower).
The record links to 7 conditions, with Microtia appearing as the primary indexed condition, and to 0 interventions.
NCT04351893 lists 10 locations in 5 states (Other, California, North Carolina).
Frequently Asked Questions
What is clinical trial NCT04351893 about?
NCT04351893 is a clinical study titled "Craniofacial Microsomia: Accelerating Understanding of the Significance and Etiology". The CAUSE study is a multicenter study, with domestic (n=4) and international (n=6) study sites. Children and young adults (ages 0-18) who have microtia and/or craniofacial microsomia and their parents are invited to participate. Children and parents are asked to provide a DNA sample (blood or saliv...
What is the current status of trial NCT04351893?
This trial is currently completed. The enrollment target is 935 participants. The study started on 2018-02-23. Estimated completion is 2023-08-30.
What conditions does trial NCT04351893 study?
This clinical trial studies the following conditions: Microtia, Microtia-Anotia, Craniofacial Microsomia, Hemifacial Microsomia, Goldenhar Syndrome.
Who is sponsoring clinical trial NCT04351893?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04351893 being conducted?
This trial has 10 study locations across California, North Carolina, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Microtia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
RECRUITING
-
Evaluation of the Auryzon™ EAR 2.0 System in Ear Reconstruction
RECRUITING · NA
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519007 · 936 participants · NA
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- NCT06855277 · 940 participants · Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI